HK1170166A1 - Pharmaceutical composition for improving solubility of prasugrel and its preparation method - Google Patents
Pharmaceutical composition for improving solubility of prasugrel and its preparation methodInfo
- Publication number
- HK1170166A1 HK1170166A1 HK12110932.6A HK12110932A HK1170166A1 HK 1170166 A1 HK1170166 A1 HK 1170166A1 HK 12110932 A HK12110932 A HK 12110932A HK 1170166 A1 HK1170166 A1 HK 1170166A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- prasugrel
- preparation
- pharmaceutical composition
- improving solubility
- solubility
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101586695A CN102232949A (zh) | 2010-04-27 | 2010-04-27 | 提高药物溶出度的组合物及其制备方法 |
PCT/CN2011/073162 WO2011134369A1 (zh) | 2010-04-27 | 2011-04-22 | 提高普拉格雷溶出度的药物组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1170166A1 true HK1170166A1 (en) | 2013-02-22 |
Family
ID=44860861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12110932.6A HK1170166A1 (en) | 2010-04-27 | 2012-10-31 | Pharmaceutical composition for improving solubility of prasugrel and its preparation method |
Country Status (6)
Country | Link |
---|---|
US (1) | US9050328B2 (xx) |
EP (1) | EP2564847B1 (xx) |
JP (1) | JP5887040B2 (xx) |
CN (2) | CN102232949A (xx) |
HK (1) | HK1170166A1 (xx) |
WO (1) | WO2011134369A1 (xx) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009011619A (es) | 2007-04-27 | 2010-01-18 | Cydex Pharmaceuticals Inc | Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso. |
WO2010132711A1 (en) * | 2009-05-13 | 2010-11-18 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
BR112013016734A2 (pt) | 2010-12-31 | 2019-09-24 | Saint Gobain Ceramics | partículas abrasivas com formas particulares e métodos de deformação de tais partículas |
CN102675338A (zh) * | 2011-03-11 | 2012-09-19 | 上海现代制药股份有限公司 | 微粉化普拉格雷及其药用组合物 |
WO2013003830A2 (en) | 2011-06-30 | 2013-01-03 | Saint-Gobain Ceramics & Plastics, Inc. | Abrasive articles including abrasive particles of silicon nitride |
CN103764349B (zh) | 2011-06-30 | 2017-06-09 | 圣戈本陶瓷及塑料股份有限公司 | 液相烧结碳化硅研磨颗粒 |
US9517546B2 (en) | 2011-09-26 | 2016-12-13 | Saint-Gobain Ceramics & Plastics, Inc. | Abrasive articles including abrasive particulate materials, coated abrasives using the abrasive particulate materials and methods of forming |
ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
PT3738434T (pt) | 2011-12-28 | 2023-11-13 | Global Blood Therapeutics Inc | Intermediários para obter compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos |
EP3851248B1 (en) | 2011-12-30 | 2024-04-03 | Saint-Gobain Ceramics & Plastics, Inc. | Composite shaped abrasive particles and method of forming same |
WO2013102176A1 (en) | 2011-12-30 | 2013-07-04 | Saint-Gobain Ceramics & Plastics, Inc. | Forming shaped abrasive particles |
EP3517245B1 (en) | 2011-12-30 | 2023-12-13 | Saint-Gobain Ceramics & Plastics Inc. | Shaped abrasive particle and method of forming same |
US8840696B2 (en) | 2012-01-10 | 2014-09-23 | Saint-Gobain Ceramics & Plastics, Inc. | Abrasive particles having particular shapes and methods of forming such particles |
WO2013106597A1 (en) | 2012-01-10 | 2013-07-18 | Saint-Gobain Ceramics & Plastics, Inc. | Abrasive particles having complex shapes and methods of forming same |
US9242346B2 (en) | 2012-03-30 | 2016-01-26 | Saint-Gobain Abrasives, Inc. | Abrasive products having fibrillated fibers |
IN2014DN10170A (xx) | 2012-05-23 | 2015-08-21 | Saint Gobain Ceramics | |
WO2014005120A1 (en) | 2012-06-29 | 2014-01-03 | Saint-Gobain Ceramics & Plastics, Inc. | Abrasive particles having particular shapes and methods of forming such particles |
CN102764264A (zh) * | 2012-07-25 | 2012-11-07 | 杭州和泽医药科技有限公司 | 一种具高溶出度的塞来昔布固体组合物、制备方法及应用 |
RU2614488C2 (ru) | 2012-10-15 | 2017-03-28 | Сен-Гобен Абразивс, Инк. | Абразивные частицы, имеющие определенные формы, и способы формирования таких частиц |
CN103012427B (zh) * | 2012-11-26 | 2015-07-08 | 天津大学 | 一种普拉格雷盐酸盐乙醇溶剂化物及其制备方法 |
CN103893137B (zh) * | 2012-12-27 | 2017-09-29 | 上海创诺制药有限公司 | 一种制备普拉格雷片剂的方法 |
JP2016503731A (ja) | 2012-12-31 | 2016-02-08 | サン−ゴバン セラミックス アンド プラスティクス,インコーポレイティド | 粒子材料およびその形成方法 |
CN111454200A (zh) | 2013-03-15 | 2020-07-28 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
SG10201802911RA (en) | 2013-03-15 | 2018-05-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
CA2902711C (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EP4364891A2 (en) | 2013-03-29 | 2024-05-08 | Saint-Gobain Abrasives, Inc. | Abrasive particles having particular shapes and methods of forming such particles |
TW201502263A (zh) | 2013-06-28 | 2015-01-16 | Saint Gobain Ceramics | 包含成形研磨粒子之研磨物品 |
US20160206604A1 (en) * | 2013-08-26 | 2016-07-21 | Global Blood Therapeutics, Inc. | Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s) |
CN103467484B (zh) * | 2013-08-30 | 2014-11-19 | 海南灵康制药有限公司 | 一种微粉化的普拉格雷及其盐的化合物及药物组合物 |
CN104434805B (zh) * | 2013-09-22 | 2017-09-29 | 成都盛迪医药有限公司 | 一种替格瑞洛固体分散体及其制备方法 |
JP2016538149A (ja) | 2013-09-30 | 2016-12-08 | サン−ゴバン セラミックス アンド プラスティクス,インコーポレイティド | 形状化研磨粒子及び形状化研磨粒子を形成する方法 |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
CA2934938C (en) | 2013-12-31 | 2019-04-30 | Saint-Gobain Abrasives, Inc. | Abrasive article including shaped abrasive particles |
US9771507B2 (en) | 2014-01-31 | 2017-09-26 | Saint-Gobain Ceramics & Plastics, Inc. | Shaped abrasive particle including dopant material and method of forming same |
SI3102208T1 (sl) | 2014-02-07 | 2021-07-30 | Global Blood Therapeutics, Inc. | Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida |
KR101884178B1 (ko) | 2014-04-14 | 2018-08-02 | 생-고뱅 세라믹스 앤드 플라스틱스, 인코포레이티드 | 형상화 연마 입자들을 포함하는 연마 물품 |
US10557067B2 (en) | 2014-04-14 | 2020-02-11 | Saint-Gobain Ceramics & Plastics, Inc. | Abrasive article including shaped abrasive particles |
US9902045B2 (en) | 2014-05-30 | 2018-02-27 | Saint-Gobain Abrasives, Inc. | Method of using an abrasive article including shaped abrasive particles |
US9707529B2 (en) | 2014-12-23 | 2017-07-18 | Saint-Gobain Ceramics & Plastics, Inc. | Composite shaped abrasive particles and method of forming same |
US9914864B2 (en) | 2014-12-23 | 2018-03-13 | Saint-Gobain Ceramics & Plastics, Inc. | Shaped abrasive particles and method of forming same |
US9676981B2 (en) | 2014-12-24 | 2017-06-13 | Saint-Gobain Ceramics & Plastics, Inc. | Shaped abrasive particle fractions and method of forming same |
KR101561406B1 (ko) * | 2015-02-02 | 2015-10-16 | 환인제약 주식회사 | 두타스테라이드 함유 고체 분산체 및 이를 포함하는 조성물 |
CN107636109A (zh) | 2015-03-31 | 2018-01-26 | 圣戈班磨料磨具有限公司 | 固定磨料制品和其形成方法 |
TWI634200B (zh) | 2015-03-31 | 2018-09-01 | 聖高拜磨料有限公司 | 固定磨料物品及其形成方法 |
CA2988012C (en) | 2015-06-11 | 2021-06-29 | Saint-Gobain Ceramics & Plastics, Inc. | Abrasive article including shaped abrasive particles |
EP3156049A1 (en) | 2015-10-15 | 2017-04-19 | Alembic Pharmaceuticals Limited | Pharmaceutical composition of prasugrel |
MA43373A (fr) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde |
SI3455321T1 (sl) | 2016-05-10 | 2022-10-28 | Saint-Gobain Ceramics & Plastics, Inc. | Metode oblikovanja abrazivnih delcev |
KR102422875B1 (ko) | 2016-05-10 | 2022-07-21 | 생-고뱅 세라믹스 앤드 플라스틱스, 인코포레이티드 | 연마 입자들 및 그 형성 방법 |
TWI752307B (zh) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | 新穎化合物及製造化合物之方法 |
WO2018064642A1 (en) | 2016-09-29 | 2018-04-05 | Saint-Gobain Abrasives, Inc. | Fixed abrasive articles and methods of forming same |
TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
GR1009230B (el) * | 2016-10-12 | 2018-02-22 | Φαρματεν Αβεε | Φαρμακευτικο σκευασμα που περιλαμβανει βεσυλικη πρασουγρελη |
EP3528790A1 (en) * | 2016-10-21 | 2019-08-28 | Laboratorios Lesvi S.L. | Pharmaceutical formulations of prasugrel and processes for the preparation thereof |
CN109922807A (zh) | 2016-11-02 | 2019-06-21 | 广东东阳光药业有限公司 | 维拉佐酮包合物及其组合物和制备方法 |
US10563105B2 (en) | 2017-01-31 | 2020-02-18 | Saint-Gobain Ceramics & Plastics, Inc. | Abrasive article including shaped abrasive particles |
US10759024B2 (en) | 2017-01-31 | 2020-09-01 | Saint-Gobain Ceramics & Plastics, Inc. | Abrasive article including shaped abrasive particles |
WO2018236989A1 (en) | 2017-06-21 | 2018-12-27 | Saint-Gobain Ceramics & Plastics, Inc. | PARTICULATE MATERIALS AND METHODS OF FORMATION THEREOF |
CN110711180B (zh) * | 2018-07-13 | 2022-03-29 | 武汉武药科技有限公司 | 一种替格瑞洛组合物及其制备方法 |
US20210308116A1 (en) | 2018-07-13 | 2021-10-07 | Council Of Scientific And Industrial Research | Solid dispersion comprising an anticancer compound for improved solubility and efficacy |
US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
WO2021133901A1 (en) | 2019-12-27 | 2021-07-01 | Saint-Gobain Ceramics & Plastics, Inc. | Abrasive articles and methods of forming same |
JP7128543B2 (ja) | 2020-12-25 | 2022-08-31 | 株式会社レーベン | 冷凍庫 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1321192C (en) * | 1988-04-20 | 1993-08-10 | Abdul Majid | Inclusion complexes of cyclodextrins by agglomeration |
MX349787B (es) * | 2006-04-04 | 2017-08-11 | Kg Acquisition Llc | Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido. |
US7622268B2 (en) | 2006-10-27 | 2009-11-24 | Inova Diagnostics, Inc. | Methods and assays for detecting GP73-specific autoantibodies |
US20100062066A1 (en) * | 2006-11-14 | 2010-03-11 | Acusphere, Inc | Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration |
WO2008072534A1 (ja) * | 2006-12-07 | 2008-06-19 | Daiichi Sankyo Company, Limited | マンニトール又は乳糖を含有する固形製剤 |
WO2008086113A1 (en) | 2007-01-08 | 2008-07-17 | Cypress Semiconductor Corporation | Low temperature oxide formation |
MX2009011619A (es) * | 2007-04-27 | 2010-01-18 | Cydex Pharmaceuticals Inc | Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso. |
CN101456864B (zh) * | 2007-12-11 | 2011-04-13 | 鲁南制药集团股份有限公司 | 普拉格雷硫酸盐、组合物及其制备方法 |
CN101177430A (zh) * | 2007-12-11 | 2008-05-14 | 鲁南制药集团股份有限公司 | 氢化吡啶衍生物及其盐的制备方法 |
WO2010015144A1 (zh) * | 2008-08-02 | 2010-02-11 | 鲁南制药集团股份有限公司 | 普拉格雷硫酸氢盐及其药物组合物和应用 |
CN101554378B (zh) * | 2008-04-09 | 2011-01-12 | 鲁南制药集团股份有限公司 | 含有普拉格雷的药物组合物 |
WO2010094471A1 (en) * | 2009-02-17 | 2010-08-26 | Krka, D. D., Novo Mesto | Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation |
DE102009010159B4 (de) | 2009-02-23 | 2015-12-03 | Carl Zeiss Ag | Vorrichtung und Verfahren zur Abstandsmessung |
CN101579337A (zh) * | 2009-02-25 | 2009-11-18 | 牛华英 | 氯吡格雷组合物及其制备方法 |
WO2010132711A1 (en) * | 2009-05-13 | 2010-11-18 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
CN101633662A (zh) * | 2009-07-30 | 2010-01-27 | 巢杰 | 普拉格雷的药用酸加成盐及其制备方法和药物应用 |
DE102009036646A1 (de) * | 2009-08-07 | 2011-02-10 | Ratiopharm Gmbh | Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon |
EP2360159A1 (de) * | 2010-02-11 | 2011-08-24 | Ratiopharm GmbH | Prasugrel in mikronisierter, kristalliner Form und pharmazeutische Zusammensetzung davon |
EP2377520A1 (de) * | 2010-03-24 | 2011-10-19 | Ratiopharm GmbH | Pharmazeutische Zusammensetzung des Prasugrels |
CN101810611A (zh) * | 2010-04-10 | 2010-08-25 | 山东新华制药股份有限公司 | 普拉格雷及其酸加成盐的环糊精包合物及其制备方法 |
-
2010
- 2010-04-27 CN CN2010101586695A patent/CN102232949A/zh active Pending
-
2011
- 2011-04-22 CN CN201180015701.7A patent/CN102811718B/zh not_active Expired - Fee Related
- 2011-04-22 US US13/643,197 patent/US9050328B2/en not_active Expired - Fee Related
- 2011-04-22 JP JP2013506469A patent/JP5887040B2/ja not_active Expired - Fee Related
- 2011-04-22 WO PCT/CN2011/073162 patent/WO2011134369A1/zh active Application Filing
- 2011-04-22 EP EP11774360.9A patent/EP2564847B1/en active Active
-
2012
- 2012-10-31 HK HK12110932.6A patent/HK1170166A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN102811718B (zh) | 2015-01-28 |
US9050328B2 (en) | 2015-06-09 |
JP5887040B2 (ja) | 2016-03-16 |
EP2564847A4 (en) | 2013-10-02 |
JP2013525386A (ja) | 2013-06-20 |
EP2564847B1 (en) | 2016-11-23 |
CN102811718A (zh) | 2012-12-05 |
CN102232949A (zh) | 2011-11-09 |
WO2011134369A1 (zh) | 2011-11-03 |
EP2564847A1 (en) | 2013-03-06 |
US20130045251A1 (en) | 2013-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1170166A1 (en) | Pharmaceutical composition for improving solubility of prasugrel and its preparation method | |
HK1250313A1 (zh) | 穩定的藥物組合物和使用所述組合物的方法 | |
HK1175947A1 (en) | Pharmaceutical compositions and methods of making same | |
IL222199A0 (en) | Process for preparation of dopo-derived compounds and compositions thereof | |
EP2623100A4 (en) | PREPARATION FOR IMPROVING THE SOLUBILITY OF A POOR SOLVENT MEDICAMENT | |
PT2413912T (pt) | Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir | |
GB201302653D0 (en) | Pharmaceutical compositions and methods of treatment | |
EP2666471A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RATE AND STOMACH, AND METHOD FOR THE PREPARATION THEREOF | |
ZA201403195B (en) | Pharmaceutical compositions of hydrophobic camptothecin derivatives | |
IL225606A0 (en) | A method for preparing an inactive supplement suitable for pharmaceutical use | |
EP2555787A4 (en) | CURCUMIN FORMULATION HAVING ENHANCED CURCUMIN BIOAVAILABILITY AND METHOD OF PREPARATION AND TREATMENT THEREOF | |
IL231505A0 (en) | Pharmaceutical preparation and method for its production | |
EP2601200A4 (en) | PREPARATION FROM PRASUGRELHYDROCHLORIDE | |
HK1193050A1 (zh) | 用於治療早泄的藥物組合物以及用於治療早泄的方法 | |
EP2586430A4 (en) | PHARMACEUTICAL COMPOSITION IN WHICH THE SOLUBILITY OF A PARTIALLY SOLUBLE TRICYCLIC DERIVATIVE IS IMPROVED | |
GB201002278D0 (en) | composition and method of preparation | |
EP2634192A4 (en) | PROCESS FOR THE PREPARATION OF A FOSAMPRENAVIR DERIVATIVE AND ITS INTERMEDIATES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190420 |